Scholarlink

<p>Episode 2 in our podcast series focuses on the critical challenge of identifying patients with <i>HER2</i>-mutant non-small cell lung cancer (NSCLC). We discuss why timely and comprehensive testing for <i>HER2</i> mutations is vital for optimizing patient outcomes and how next-generation sequencing and molecular profiling are integrated into clinical practice. This episode covers the practical aspects and evolving standards of <i>HER2</i> mutation testing, including the use of tumor and liquid biopsies, and addresses real-world barriers such as cost, access, and awareness. We also explore potential solutions, such as reflex testing and collaboration with molecular pathologists, to overcome current diagnostic challenges. This episode emphasizes the importance of accurate and early molecular diagnosis in ensuring patients receive the most effective, personalized therapies as the treatment landscape for <i>HER2</i>-mutant NSCLC continues to advance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HER2-Mutant Non-Small Cell Lung Cancer Podcast: Finding Patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月13日

查看全文
  • Vivek Subbiah,
  • Martin Dietrich

摘要

Episode 2 in our podcast series focuses on the critical challenge of identifying patients with HER2-mutant non-small cell lung cancer (NSCLC). We discuss why timely and comprehensive testing for HER2 mutations is vital for optimizing patient outcomes and how next-generation sequencing and molecular profiling are integrated into clinical practice. This episode covers the practical aspects and evolving standards of HER2 mutation testing, including the use of tumor and liquid biopsies, and addresses real-world barriers such as cost, access, and awareness. We also explore potential solutions, such as reflex testing and collaboration with molecular pathologists, to overcome current diagnostic challenges. This episode emphasizes the importance of accurate and early molecular diagnosis in ensuring patients receive the most effective, personalized therapies as the treatment landscape for HER2-mutant NSCLC continues to advance.